News and Announcements
Medication Adherence Platform, MedAdvisor, Lists on the ASX
- Published December 01, 2015 10:46AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st December 2015, ASX Announcement
- MedAdvisor raises $5m in oversubscribed public offer
- MedAdvisor commences trading under ticker code MDR
- MedAdvisor announces new medication training relationship with Amgen
MedAdvisor Limited (MedAdvisor or Company) an Australian software developer focused on improving health outcomes by placing patients at the centre of connected health platforms, has been re-admitted to the Australian Securities Exchange. MedAdvisor, trading under the ticker code MDR, commences trading today following a reverse takeover of Exalt Resources Limited (ASX: ERD) by MedAdvisor International Pty Ltd.
The company also announces it has entered a new medication training relationship with Amgen, the world’s largest independent biotechnology company, which currently markets eight products in Australia for the treatment of cancer, kidney disease, bone disease and other serious illnesses.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
